Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy “REGATТA” results)
- Authors: Shakhmatova O.O.1, Komarov A.L.1, Korobkova V.V.1, Yarovaya E.B.1,2, Andreevskaya M.V.1, Shuleshova A.G.1, Panchenko E.P.1
-
Affiliations:
- National Medical Research Center of Cardiology
- Lomonosov Moscow State University
- Issue: Vol 92, No 9 (2020)
- Pages: 30-38
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/46851
- DOI: https://doi.org/10.26442/00403660.2020.09.000699
- ID: 46851
Cite item
Full Text
Abstract
Introduction. Upper gastrointestinal (UGI) bleeding is a common complication of antiplatelet therapy. Data from real clinical practice that characterize the range of risk factors for UGI bleeding, prophylactic proton pump inhibitors (PPIs) therapy, bleeding frequency and their long-term effects in patients with stable coronary artery disease (CAD) are limited.
Aim. To identify predictors of UGI bleeding in patients with stable CAD, to assess the role of PPI in the prevention of bleeding and the long-term prognosis of patients after bleeding.
Materials and methods. 934 patients with stable CAD (median age 61 [53–68] years, 78.6% men) were included in the single institution prospective REGistry of Long-term AnTithrombotic TherApy (REGATTA). Atherosclerosis of peripheral arteries (APA) and abdominal aortic aneurysm (AAA) screening was performed by doctor decision, as well as esophagogastroduodenoscopy. 76% of patients received dual antiplatelet therapy for 6–12 months after elective PCI. PPIs were prescribed in 28.3% of cases.
Results. The median follow-up was 2.5 [1.1–5.1] years. The frequency of overt UGI bleeding was 1.9 per 100 patients per year. Anamnesis of peptic ulcer disease (OR 4.7; 95% CI 1.9–11.8; p=0.001), erosion of the upper gastrointestinal tract (OR 6.7; 2.7–16.6; p=0.00004 ), as well as concomitant diseases associated with a decrease in blood supply to the mucosa, such as heart failure – HF (OR 6.1; 2.3–16.0; p=0.0002), AAA (OR 9.3; 2.5–34.2; p=0.0008) and APA (OR 2.3; 0.98–5.5; p=0.05) turned out to be independent predictors of UGI bleeding. The frequency of AAA among those who underwent UGI bleeding was 19.6% (in patients without bleeding – 1.4%; p<0.001). 90.2% of patients with UGI bleeding received PPI; the frequency of UGI bleeding in patients receiving pantoprazole and omeprazole did not differ significantly. After UGI bleeding, rebleeding rate was 7.8%, thrombotic events (TE) rate – 31.4%, mortality rate – 17.7% for 30 days, 19.4% for 1 year and 35.3% for the entire observation period. The predictors of deaths were AAA (OR 92.5; 7.7–107.9; p<0.0001), APA (OR 4.2; 1.03–17.2; p=0.045) and HF (OR 34.5; 8.5–140.6; p<0.0001). The worst prognosis was expected for patients who underwent UGI bleeding and thrombotic events: 2/3 of these patients died.
Conclusion. In a prospective analysis of patients with stable CAD, we identified UGI bleeding was a significant risk factor for late thromboembolism and death, compared with patients without bleeding. Predictors of UGI bleeding and poor prognosis are factors that indicate atherothrombotic burden – abdominal aortic aneurysm, peripheral atherosclerosis and HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04347200.
Full Text
##article.viewOnOriginalSite##About the authors
O. O. Shakhmatova
National Medical Research Center of Cardiology
Author for correspondence.
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0002-4616-1892
к.м.н., науч. сотр. отд. клинических проблем атеротромбоза ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowA. L. Komarov
National Medical Research Center of Cardiology
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0001-9141-103X
д.м.н., вед. науч. сотр. отд. клинических проблем атеротромбоза ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowV. V. Korobkova
National Medical Research Center of Cardiology
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0003-3536-9177
аспирант отд. клинических проблем атеротромбоза ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowE. B. Yarovaya
National Medical Research Center of Cardiology; Lomonosov Moscow State University
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0002-6615-4315
д.ф.-м.н., вед. науч. сотр. научно-организационного отд. ФГБУ «НМИЦ кардиологии», проф. каф. теории вероятностей механико-математического фак-та ФГБОУ ВО «МГУ им. М.В. Ломоносова»
Russian Federation, MoscowM. V. Andreevskaya
National Medical Research Center of Cardiology
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0001-5917-0205
к.м.н., науч. сотр. отд. ультразвуковых методов исследований ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowA. G. Shuleshova
National Medical Research Center of Cardiology
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0003-1201-5931
д.м.н., проф., зав. эндоскопическим отд-нием ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowE. P. Panchenko
National Medical Research Center of Cardiology
Email: olga.shahmatova@gmail.com
ORCID iD: 0000-0002-9158-2522
д.м.н., проф., гл. науч. сотр. отд. клинических проблем атеротромбоза ФГБУ «НМИЦ кардиологии»
Russian Federation, MoscowReferences
- Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708-13, 1713a-1713b. doi: 10.1093/eurheartj/eht042
- Ducrocq G, Schulte PJ, Becker RC, et al. Association of spontaneous and procedure-related bleeds with short- and longterm mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015;11:737-45. doi: 10.4244/eijy14m09_11
- Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2010;56(24):2051-66. doi: 10.1016/j.jacc.2010.09.010
- Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-8. doi: 10.1056/nejmoa012877
- Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-25. doi: 10.1016/S0140-6736(09)61246-0
- Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-17. doi: 10.1056/nejmoa1007964
- Moayyedi P, Eikelboom JW, Bosch J, et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 2019;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041
- Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507-15. doi: 10.1111/j.1572-0241.2006.01062.x
- Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82-8. doi: 10.1053/j.gastro.2009.09.063
- Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15:S5. doi: 10.1186/ar4177
- Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:267-315. doi: 10.1093/eurheartj/ehv320
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-77. doi: 10.1093/eurheartj/ehx393
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213-60. doi: 10.1093/eurheartj/ehx419
- Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. doi: 10.1093/eurheartj/ehz425
- Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25(2):166-81. doi: 10.1016/j.ehj.2003.10.013
- Romera Barba E, Sánchez Pérez A, Bertelli Puche J, et al. Primary aorto-duodenal fistula: A rare but potentially fatal cause of gastrointestinal bleeding. Cir Esp. 2015;93(2):121-3. doi: 10.1016/j.cireng.2014.12.008
- Jensen BES, Hansen JM, Larsen KS, et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol Hepatol. 2017;29:1118-25. doi: 10.1097/MEG.0000000000000934
- Jones AW, Kirk RS, Bloor K. The association between aneurysm of the abdominal aorta and peptic ulceration. Gut. 1970;11:679-84. doi: 10.1136/gut.11.8.679
- Cheng SW, Fok M, Wong J. Peptic ulcers and abdominal aortic aneurysms. J Gastroenterol Hepatol. 1992;7(3):302-4. doi: 10.1111/j.1440-1746.1992.tb00985.x
- Konno H, Kaneko H, Maruo Y, et al. Prevention of gastric ulcer or acute gastric mucosal lesions accompanying bleeding after abdominal aortic aneurysm surgery. World J Surg. 1994;18(6):944-7. doi: 10.1007/bf00299117
- Pabst TS, Bernhard VM, McIntyre KE, et al. Gastrointestinal bleeding after aortic surgery. J Vasc Surg. 1988;8:280-5. doi: 10.1016/0741-5214(88)90279-0
- Konno H, Sakaguchi S, Hachiya T. Bleeding peptic ulcer after abdominal aortic aneurysm surgery. Arch Surg. 1991;126(7):894-7. doi: 10.1001/archsurg.1991.01410310104016
- Elkeles A. Gastric ulcer in the aged and calcified atherosclerosis. AJR Am J Roentgenol. 1964;91:744-50.
- Rabkin SW. The Role Matrix Metalloproteinases in the Production of Aortic Aneurysm. Prog Mol Biol Transl Sci. 2017;147:239-65. doi: 10.1016/bs.pmbts.2017.02.002
- Li SL, Zhao JR, Ren XY, et al. Increased expression of matrix metalloproteinase-9 associated with gastric ulcer recurrence. World J Gastroenterol. 2013;19(28):4590-5. doi: 10.3748/wjg.v19.i28.4590
- Yeh Y, Cheng H, Chang W, et al. Matrix metalloproteinase-3 promoter polymorphisms but not dupA-H. pylori correlate to duodenal ulcers in H. pylori-infected females. BMC Microbiol. 2010;10:218. doi: 10.1186/1471-2180-10-218
- Kwon OS, Jung HS, Bae KS, et al. Increased serum activity of matrix metalloproteinase-9 in patients with acute variceal bleeding. Gut Liver. 2012;6(2):249-55. doi: 10.5009/gnl.2012.6.2.249
- Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056
- Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706-15. doi: 10.1053/j.gastro.2017.01.031
- Mohan V, Talmi-Frank D, Arkadash V, et al. Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine. Metalloproteinases In Medicine. 2016;3:31-47. doi: 10.2147/mnm.s65143
- Singh LP, Mishra A, Saha D, Swarnakar S. Doxycycline blocks gastric ulcer by regulating matrix metalloproteinase-2 activity and oxidative stress. World J Gastroenterol. 2011;17(28):3310-21. doi: 10.3748/wjg.v17.i28.3310
- Nagata N, Sakurai T, Shimbo T, et al. Acute severe gastrointestinal tract bleeding is associated with an increased risk of thromboembolism and death. Clin Gastroenterol Hepatol. 2017;15:1882-9. doi: 10.1016/j.cgh.2017.06.028
- Laursen SB, Hansen JM, Hallas J, et al. The excess long-term mortality in peptic ulcer bleeding is explained by nonspecific comorbidity. Scand J Gastroenterol. 2015;50:145-52. doi: 10.3109/00365521.2014.992365